Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: Increased concentrations in rheumatoid arthritis

Annals of the Rheumatic Diseases

Volumn 58, Issue 8, 1999, Pages 488-492

  Slot, Ole ^a   Brünner, Nils ^b   Locht, Henning ^a   Oxholm, Peter ^a   Stephens, Ross W ^b  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b FINSEN LABORATORY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; UROKINASE RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE ASSOCIATION; EROSION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REACTIVE ARTHRITIS; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME;

EID: 0032774610     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.58.8.488     Document Type: Article

References (29)

1. 1 Romer J, Bugge TH, Pyke C, Lund L, Flick MJ, Degen J L, et al. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996;2:287-92.
2. 2 Vassalli J-D, Sappino A-P, Belin D. The plasminogen activator/plasmin system. J Clin Invest 1991;88:1067-72.
3. 3 Danø K, Behrendt N, Brünner N, Ellis V, Ploug M, Pyke C. The urokinase receptor. Protein structure and role in plasminogen activation and cancer invasion. Fibrinolysis 1994;8 (suppl 1):189-203.
4. 4 Campbell IK, Piccoli DS, Roberts MJ, Muirden KD, Hamilton JA. Effects of tumor necrosis factor α and β on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum 1990;33:542-52.
5. 5 Brommer EJP, Dooijewaard G, Dijkmans BAC, Breedveld FC. Depression of tissue-type plasminogen activator and enhancement of urokinase-type plasminogen activator as an expression of local inflammation. Thromb Haemost 1992;68:180-4.
6. 6 Kirchheimer JC, Remold HG, Wanivenhaus A, Binder BR. Increased proteolytic activity on the surface of monocytes from patients with rheumatoid arthritis. Arthritis Rheum 1991;34:1430-3.
7. 7 Zacharski LR, Brown EF, Memoli VA, Kisiel W, Kudryk BJ, Rousseau SM, et al. Pathways of coagulation activation in situ in rheumatoid synovial tissue. Clin Immunol Immunopathol 1993;63:155-62.
8. 8 Belcher C, Fawthrop F, Bunning R, Doherty M. Plasminogen activators and their inhibitors in synovial fluids from normal, osteoarthritis, and rheumatoid arthritis knees. Ann Rheum Dis 1996;55:230-6.
9. 9 Ronday HK, Smits HH, van Muijen GNP, Pruszczynski MSM, Dolhain RJEM, van Langelaan EJ, et al. Difference in expression of the plasminogen activation system in synovial tissue of patients with rheumatoid arthritis and osteoarthritis. Br J Rheumatol 1996;35:416-23.
10. 10 Busso N, Péclat V, So A, Sappino A-P. Plasminogen activation in synovial tissues: Difference between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997;56:550-7.
11. 11 Szekanecs Z, Haines GK, Koch AE. Differential expression of the urokinase receptor (CD87) in arthritic and normal synovial tissues. J Clin Pathol 1997;50:314-19.
12. 12 Cerinic MM, Generini S, Partsch G, Pignone A, Dini G, Kontinen YT, et al. Synoviocytes from osteoarthritis and rheumatoid arthritis produce plasminogen activators and plasminogen activator inhibitor-1 and display u-PA receptors on their surface. Life Sci 1998;63:441-53.
13. 13 Ronday HK, Smits HH, Quax PHA, van der Pluijm G, Löwik CWGM, Breedveld FC, et al. Bone matrix degradation by the plasminogen activation system, possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997; 36:9-15.
14. 14 Mochan E, Uhl J. Elevations of synovial fluid plasminogen activator in patients with rheumatoid arthritis. J Rheumatol 1984;11:123-8.
15. 15 Kikuchi H, Tanaka S, Matsuo O. Plasminogen activator in synovial fluid from patients with rheumatoid arthritis. J Rheumatol 1987;14:439-45.
16. 16 Saxne T, Lecander I, Geborek P. Plasminogen activators and plasminogen activator inhibitors in synovial fluid. Difference between inflammatory joint disorders and osteoarthritis. J Rheumatol 1993;20:91-6.
17. 17 Kummer JA, Abbink JJ, de Boer J-P, Roem D, Nieuwenhuys EJ, Kamp AM, et al. Analysis of intraarticular fibrinolytic pathways in patients with inflammatory and noninflammatory joint diseases. Arthritis Rheum 1992;35:884-93.
18. 18 Brommer EJP, Dooijewaard G, Dijkmans BAC, Breedveld FC. Plasminogen activators in synovial fluid and plasma from patients with arthritis. Ann Rheum Dis 1992;51: 965-8.
19. 19 Rønne E, Pappot H, Grøndahl-Hansen J, Høyer-Hansen G, Plesner T, Hansen NE, et al. The receptor for urokinase plasminogen activator is present in plasma from healthy donors and elevated in patients with paroxymal nocturnal haemoglobinuria. Br J Haematol 1995;89:576-81.
20. 20 Behrendt N, Stephens RW. The urokinase receptor. Fibrinolysis and Proteolysis 1998;12:191-204.
21. 21 Stephens RW, Pedersen AN, Nielsen HJ, Hamers MJAG, Hoøyer-Hansen G, Roønne E, et al. ELISA determination of soluble urokinase receptor in blood from healthy donors and cancer patients. Clin Chem 1997;43:1876-84.
22. 22 Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
23. 23 Vitali C, Bombardieri S, Moutsopoulos HM, Balestrieri G, Bencivelli W, Berstein RM, et al. Preliminary criteria for the classification of Sjögren's syndrome. Arthritis Rheum 1993;36:340-7.
24. 24 Manthorpe R, Oxholm P, Prause JU, Schiödt M. The Copenhagen criteria for Sjögrens syndrome. Scand J Rheumatol 1986;S61:22-5.
25. 25 Scott DL, van Reil PL, van dur Heide D, Benke AS. Assessing disease activity in rheumatoid arthritis. In: The EULAR handbook of standard methods. London: EULAR, 1993.
26. 26 Fibbi G, Pucci M, Serni U, Cerinic MM, Del Rosso M. Antisense targeting of the urokinase receptor blocks urokinase-dependent proliferation, chemoinvasion, and chemotaxis of human synovial cells and chondrocytes in vitro. Proc Assoc Am Physicians 1998;110:340-50.
27. 27 Del Rosso M, Fibbi G, Pucci M, Cerinic MM. Antisense oligonucleotides against the urokinase receptor: a therapeutic strategy for the control of cell invasion in rheumatoid arthritis and cancer. Clin Exp Rheumatol 1998;16:389-93.
28. 28 Busso N, So A. Urokinase in rheumatoid arthritis: causal or coincidal? Ann Rheum Dis 1997;56:705-6.
29. 20 Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest 1998;102:41-50.